| Autor: |
Giulia Meoni, Nicola Libertà Decarli, Maurizio Benucci, Claudio Raspanti, Angela Stefania Ribecco |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 5, Pp 372-380 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2692-3114 |
| DOI: |
10.37349/etat.2020.00022 |
| Popis: |
Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from cytotoxic agents or small molecules against NSCLC, also tumor response may present with atypical features. Pseudoprogression (PP) is a distinct response pattern defined by a transient enlargement of the tumor burden, sustained by inflammatory cells and usually not associated with worsening of performance status (PS). Here the authors describe the case of a lung adenocarcinoma patient treated with pembrolizumab, who developed an early symptomatic PP with a dramatic global worsening of PS. Subsequently an improvement in general condition and a brilliant tumor response were observed. Tumor re-biopsy was collected after the treatment in order to support the identification of PP and to describe microenvironment modifications induce by immunotherapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
